Skip to main content

aglatimagene besadenovec

Generic: CAN-2409·Code: CAN-2409

aglatimagene besadenovec: 3 clinical trials tracked.

aglatimagene besadenovec evidence translation

What we can confirm

3 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about aglatimagene besadenovec, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors

Related indications

Prostate Cancer
Clinical Trial Registry Records (3)

A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenovec (CAN-2409) Plus Prodrug and Pembrolizumab Versus Docetaxel for Stage IV Non-Squamous Non-Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment

NCT07660094Registry updated 2026-06-22·Phase 3·CADL
Recruiting

Primary endpoint: Overall Survival

InterventionalRandomizedopen500 targetStarted 2026-06Completion 2031-101 site · United StatesCandel Therapeutics, Inc.

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients

NCT04495153Registry updated 2025-08-22·Phase 2·CADL
Active, not recruiting

Primary endpoint: Response rate

Interventionalopen90 enrolledStarted 2020-10Completion 2026-1214 sites · United StatesCandel Therapeutics, Inc.

A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer

NCT02768363Registry updated 2026-10-02·Phase 2·CADL
Active, not recruiting

Primary endpoint: Progression-free survival (PFS)

InterventionalRandomizedquadruple187 enrolledStarted 2016-05Completion 2026-1223 sites · Mexico, United StatesCandel Therapeutics, Inc.